For Pioneering Contributions to Conception and Development of Vertical-Cavity Surface-Emitting Laser (VCSEL) and Leadership in Its Practical Application TOKYO, JAPAN ...
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine ...
- For Pioneering Contributions to Conception and Development of Vertical-Cavity Surface-Emitting Laser (VCSEL) and Leadership in Its Practical Application - TOKYO, Sept. 9, 2025 /PRNewswire/ -- The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback